CN101974531A - Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell - Google Patents
Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell Download PDFInfo
- Publication number
- CN101974531A CN101974531A CN 201010293265 CN201010293265A CN101974531A CN 101974531 A CN101974531 A CN 101974531A CN 201010293265 CN201010293265 CN 201010293265 CN 201010293265 A CN201010293265 A CN 201010293265A CN 101974531 A CN101974531 A CN 101974531A
- Authority
- CN
- China
- Prior art keywords
- hiv
- cell
- mirna
- hsa
- mirnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a specific expression miRNA group susceptible to and supporting HIV (Human Immunodeficiency Virus-Type 1) in a CD4+T cell of an HIV target cell, belonging to the field of biomedicine. In the invention, a high-flux human miRNA chip is adopted, and the miRNA expression differences of CD4+T cells in three states of no stimulation, CD3/CD28 magnetic bead stimulation and PHA/IL-2 stimulation are compared and screened to obtain the specific expression miRNA group susceptible to and supporting the HIV-1 in the in CD4+T cell of the HIV target cell, wherein the specific expression miRNA group comprises 12 miRNAs in total and consists of nucleotide sequences shown as SEQ ID NO: 1-12; and target genes regulated and controlled by all the miRNAs in the specific expression miRNA group all participate in forming obvious functions (Gene Ontology, GO) of different biological effects and a signal transduction pathway, lay in key nodes or important sites in a signal transduction net (Signal-Net) and a gene regulation and control net (Gene Re Net) and are expected to be used for detecting the expression levels of the miRNAs in a sample by a method for establishing a chip, molecular hybridization and an RT-PCR (Reverse Transcription-Polymerase Chain Reaction), based on a single, multiple or all the miRNAs so as to diagnose the HIV and screen medicaments for resisting HIV cells according to the expression levels of the miRNAs.
Description
Technical field:
The present invention relates to the specifically expressing miRNA group of hiv virus target cell CD4+T cell susceptible and support HIV-1.Be the relevant miRNA of screening acquired immune deficiency syndrome (AIDS) in people microRNA class range concretely, hiv virus target cell CD4+T cell susceptible that the method for utilizing cell model and biochip technology to combine is set up and the specifically expressing miRNA group who supports HIV-1 belong to biomedical sector.
Background technology:
MicroRNA (miRNA) is the non-coding small molecule single stranded RNA of endogenous that the class found recently has 18-24 Nucleotide approximately, combine with 3 ' the end non-coding region of proteins encoded mRNA by incomplete complementary mode, cause that the degraded of said target mrna, active reduction or translation are subjected to press down, thereby genetic expression is regulated and control at post-transcriptional level.MiRNA the ontogeny of cell, propagation, apoptosis, differentiation and stress in playing the part of important role, with multiple diseases such as tumour, heart trouble, diabetes and acquired immune deficiency syndrome (AIDS) close ties are arranged all, the life cycle of the production process of some miRNA and HIV-1 (human immunodeficiency virus-type 1, human immunodeficiency virus) is associated.Therefore infer in the generating process of acquired immune deficiency syndrome (AIDS), have distinctive miRNA express spectra.
The activation of the target cell CD4+T cell that HIV-1 is natural and propagation are the prerequisites that HIV-1 is able to a large amount of breedings and extensively sends out, people's wills such as Levine were found outward in 1996, after being coated on CD3 on the magnetic bead, CD28 antibody (" CD3/CD28 beads ") simultaneously and stimulating, the CD4+T cell of activation, propagation, obtained on the contrary to resist the ability that infection can be removed virus again---behind the CD4+T cell activation from HIV-1 the infected, can remove the virus that has infected gradually, behind the CD4+T cell activation from health adult, can resist HIV-1 and not infected.We are based on this special effects, while is with the height susceptible and promote that the PHA/IL-2 active cells of virus multiplication is counterevidence, make up cell model and filter out the relevant miRNA expression map of acquired immune deficiency syndrome (AIDS), in order to the anti-safely and effectively AIDS of direct screening cell drug.
Summary of the invention:
The object of the present invention is to provide the specifically expressing miRNA group of hiv virus target cell CD4+T cell susceptible and support HIV-1.
The present invention adopts high-throughout people microRNA chip, stimulate the CD4+T cell miRNA differential expression of three kinds of states by more stimulation, the stimulation of CD3/CD28 magnetic bead and PHA/IL-2, screening obtains one group of hiv virus target cell CD4+T cell susceptible and supports the specifically expressing miRNA group of HIV-1, comprise 12 miRNA altogether, it is the sign of the anti-AIDS of combination conduct eliminating cell drug partly or entirely; This group miRNA is low the expression when CD4+T cell resistance and removing HIV-1 state, and title and the sequence of 12 miRNA among the miRNA group see Table 1;
The specifically expressing miRNA group (totally 12 miRNA) of table 1 susceptible and support HIV-1
The target gene that each miRNA regulated and control among the specifically expressing miRNA group among the present invention has all participated in causing remarkable function (the Gene Ontology of different biological effect, GO) and signal transduction pathway (pathway), simultaneously in the regulated and control network (GeneRelNet) of signal transduction network (Signal-Net) and gene, be in key event or critical role, therefore have most the representative meaning.
Description of drawings:
Fig. 1 shows special low expression miRNA in opposing and the removing state (B).
Embodiment:
The present invention is by adopting high-throughout people miRNA chip, the CD4+T cell miRNA differential expression that more stimulate, the CD3/CD28 magnetic bead stimulates (B) and PHA/IL-2 stimulation (P) three kinds of states, screening obtains one group of hiv virus target cell CD4+T cell susceptible and supports the specifically expressing miRNA group of HIV-1, comprises 12 miRNA altogether.Concrete steps are as follows:
1. the selection of sample and processing
3 routine samples are taken from Kunming, Yunnan Blood Center, are the healthy human peripheral blood White Blood Cells Concentrate.Adopt density gradient centrifugation to separate peripheral blood mononuclear cell (PBMC), adopt CD4+T Cell Isolation Kit II human test kit (Miltenyi company) that PBMC is carried out the negative sorting of magnetic bead, obtain the CD4+T cell of quiescent condition.Use the every hole 3ml trace of 6 well culture plates culture system at 37 ℃, 5%CO
2In the incubator CD4+T cell is carried out stimulated in vitro and cultivate, substratum is RPMI 1640 complete culture solutions [RPMI 1640+10%FBS+0.1mol/L HEPES (worker biotech firm is given birth in Shanghai)].The CD3/CD28 magnetic bead stimulates (B group): in 1: 3 ratio of cell magnetic bead inoculation 1 * 10
6CD4+T cells/well (Dynabeads Human T-Activator CD3/CD28, Invitrogen company) was changed half liquid in per 2 days and is gone down to posterity, and keeping cell density is 1～2 * 10
6Cell/ml.PHA/IL-2 stimulates (P group): inoculation 2 * 10
6The CD4+T cells/well, adding 5mg/ml phytohaemagglutinin (PHA) and 100U/ml interleukin-2 (IL-2) stimulates cultivation, changes half liquid and replenishes PHA and IL-2 in per 3 days.Above-mentioned cytositimulation 6 days, together with behind the total RNA of CD4+T cell extraction that does not stimulate (R group) as the sample of gene chip hybridization.
2. gene chip hybridization
2.1 total RNA extracts and purifying
Adopt mirVana RNA Isolation Kit (Applied Biosystem p/n AM1560) to extract Total RNA.
2.2 prepare the labeled reactant system
Sample mark and hybridize needed reagent and all be included among Agilent ' the s miRNA Complete Labeling and Hyb Kit (p/n 5190-0456), concrete reagent catalogue is as follows:
Calf?Intestinal?Alkaline?Phosphatase(CIP)
10×Calf?Intestinal?Phosphatase?Buffer
T4RNA?Ligase
10×T4RNA?Ligase?Buffer
Dimethyl?sulfoxide(DMSO)
Nuclease-Free?Water
Cyanine?3-pCp
10X?GE?Blocking?Agent
2X?Hi-RPM?Hybridization?Buffer
2.2.1 dephosphorylation:
2.2.1.1 with 1 * TE (pH7.5) or DNase/RNase-free water with the RNA diluted sample to 50ng/ μ L.
2.2.1.2 draw sample 2 μ L after the above-mentioned dilution to clean 1.5mL centrifuge tube, place standby on ice.
2.2.1.3 the preparation of the order shown in according to the form below dephosphorylation mixed solution:
2.2.1.4 get above-mentioned mixed solution 2 μ L to sample hose, cumulative volume is 4 μ L, rifle head suction mixing.
2.2.1.5 above-mentioned 4 μ L reaction mixtures are placed 37 ℃ of metal baths or PCR instrument, are incubated 30 minutes.This step as not carrying out following reaction immediately, should place response sample-80 ℃ of preservations standby after finishing.
2.2.2 sample sex change:
2.2.2.1 in every pipe sample, add 2.8 μ L 100%DMSO.
2.2.2.2 above-mentioned reaction mixture is placed 100 ℃ of metal bath heating 5-10 minute.Notice that the strict period is in above-mentioned scope.
2.2.2.3 after above-mentioned reaction finishes, sample hose changed in the ice-water bath rapidly cools off, and carry out following reactions steps immediately.
2.2.3 connect:
2.2.3.1 10 * T4RNA Ligase Buffer is placed 37 ℃ of incubations and vortex at interval, and until all dissolvings of precipitation, it is standby then it to be cooled to room temperature.
2.2.3.2 according to the form below preparation ligation mixed solution:
| Components | Volume(μL)per?reaction | Volume(μL)per?9reactions |
| 10×T4RNA?Ligase?Buffer | 1.0 | 9.0 |
| Cyanine3-pCp | 3.0 | 27.0 |
| T4RNA?Ligase | 0.5 | 4.5 |
| Total?Volume | 4.5 | 40.5 |
Attention: above-mentioned reaction mixture should be prepared before use, is placed on ice after preparing, and uses in 15 minutes.
2.2.3.3 get reaction mixture above the 4.5 μ L to sample hose, cumulative volume is 11.3 μ L, rifle head tap persorption is even, and is centrifugal slightly.
2.2.3.4 placed 16 ℃ of incubations 2 hours.After reaction finished, it was standby to place the vacuum concentration instrument to drain fully in sample.Attention: sample must be drained fully removing DMSO, the temperature of vacuum concentration instrument is set in 45 ℃-55 ℃ drains the time accelerating.
2.3 prepare 10 * Blocking Agent:
2.3.1 add 125 μ L nuclease-free water in freeze dried 10X * GE BlockingAgent pipe, slight vortex so that it dissolves fully, was placed on 37 ℃ of incubation 4-5 minutes in case of necessity.
2.3.2 centrifugal slightly, place standby.The 10X for preparing * GE Blocking Agent is placed on-20 ℃ and preserved 2 months, and each the thawing when using noted vortex mixing and centrifugal.
2.4 prepare the hybridization sample:
2.4.1 the metal bath of preparing 100 ℃ is standby.
2.4.2 the sample of draining is dissolved in the 18 μ L nuclease-free water again.
2.4.3 in every pipe, add 10 * GE Blocking Agent that 4.5 μ L prepare.
2.4.4 in every pipe, add 22.5 μ L, 2 * Hi-RPM Hybridization Buffer, slight vortex mixing.
2.4.5 above-mentioned reaction mixture is placed in 100 ℃ of metal baths heating 5 minutes.
2.4.6 after reaction finishes, rapidly it is gone in the ice-water bath and cooled off 5 minutes.Attention: the refrigerative time should be above 15 minutes.
2.4.7 centrifugal collection reaction solution also carries out following step immediately.
2.5 prepare the hybridization mixed solution:
2.5.1 suitable cover plate correctly is placed on the Agilent SureHyb chamber base.
2.5.2 lentamente about 45 μ L reaction solutions are drawn on the cover plate with pipettor.Attention: when drawing reaction solution, be not drawn onto precipitation, and avoid introducing bubble as far as possible.To avoid the rifle head to touch the cover plate sealing-ring simultaneously, in order to avoid the leakage of breaking.
2.5.3 chip point sample face (having " Agilent " printed words face) slowly is placed on the cover plate down.
2.5.4 assembling SureHyb chamber, and tighten.
2.5.5 rock the SureHyb chamber that assembles a little, so that all bubbles in the inside can move freely.
2.5.6 SureHyb chamber balance is placed on the shelf of hybrid heater, and temperature is set in 55 ℃, rotating speed is 20rpm.
2.5.7 hybridized 20 hours.Attention:, keep the hybridization time unanimity with in once testing.
2.6 the operating process of chip washing:
2.6.1 in Gene Expression wash buffers, add Triton X-102:
2.6.1.1 from carton, take out reagent bottle, open the lid of ectonexine.
2.6.1.2 add the Triton X-102 of 2mL 10% with pipettor.
2.6.1.3 cover lid, mixing 5-6 time turns upside down.
2.6.1.4 load onto tap, and on the bottle wall, indicate " having added Triton X-102 ".
Attention: Wash 1 and wash 2 all should add Triton X-102 according to above-mentioned steps before use.
2.6.2 preheating Gene Expression Wash Buffer 2:
2.6.2.1 in aseptic reagent bottle, pour the Gene Expression Wash Buffer 2 of 1L into.
2.6.2.2 reagent bottle is put into 37 ℃ of water-baths to spend the night.
2.6.2.3 the plate with slide-staining dish#3 places dress water is placed in 37 ℃ of water-baths and spends the night.
2.6.3 preparation machine:
With all plates that need use, shelf and magnetic bar in the experiment, thoroughly clean for several times with Milli-Q water; In the washing process in per step, use equipment such as same dishes as far as possible.
2.6.4 washing chip:
2.6.4.1 concrete washing time and temperature are as shown in the table:
| Dish | Wash?Buffer | | Time | |
| Disassembly | ||||
| 1 | GE?Wash?Buffer?1 | Room?temperature | ||
| 1st?wash | 2 | GE?Wash?Buffer?1 | Room?temperature | 5minutes |
| 2nd?wash | 3 | GE?Wash?Buffer?2 | 37℃ | 5minutes |
2.6.4.2 in slide-staining dish# 1, fill with Gene Expression Wash Buffer 1, standby in room temperature.
2.6.4.3 slide rack is placed among the slide-staining dish # 2, injects Gene Expression Wash Buffer 2 to cover slide rack.Put into a magnetic bar, then dish is placed on the magnetic stirring apparatus.
2.6.4.4 the slide-staining dish#3 of 37 ℃ of preheatings of spending the night is placed on the magnetic stirring apparatus, inject the Gene Expression Wash Buffer 2 of the preheating of spending the night, open heating unit, make temperature be controlled at 37 ℃.
2.6.4.5 from hybrid heater, take out hybridization chamber assembly, carefully take off chip/cover plate, left hand is gently put, chip faces up, immerse among the Gene Expression Wash Buffer 1, the right hand takes off cover plate with the homalocephalus tweezers from labeled one, and it is fallen in the plate, then rapidly chip is put into the slide rack that is placed on slide-staining dish#2.Repeat above-mentioned steps, place appropriate up to other chip.Open magnetic stirring apparatus, middling speed stirred 5 minutes.Attention: the rotating speed of magnetic stirring apparatus should be not too fast, the defective chip in case magnetic bar takeoffs.
After 2.6.4.6 the time finishes, take out the slide rack that is placed with chip, on the thieving paper gently control remove the liquid be infected with above, then put into slide-staining dish#3.Open magnetic stirring apparatus, middling speed stirred 5 minutes, noticed that controlled temperature is at 37 ℃.
After 2.6.4.7 the time finishes, take out slide rack, on the thieving paper gently control remove the liquid be infected with above, carry out following step immediately.Attention: can not scan immediately as chip, should place in the dark and preserve; When carrying out the chip washing of next round, use new wash buffer.
2.7 chip scanning and data are obtained:
2.7.1 chip correctly is placed among the slide holder, and the point sample placed face down puts it in the scanner then.
2.7.2 open Agilent Scan Control software, according to the form below is provided with sweep parameter:
2.7.3 being arranged to automatic filename obtains: prefix 1 is an Equipment Serial Number, prefix 2 is chip bar codes.
2.7.4 confirm that the state of scanner is " ready ", click " Scan Slot m-n ", confirm the placement location of chip.After the above-mentioned steps affirmation was errorless, the beginning chip scanning also obtained data.
3. data analysis
3.1 difference miRNA screening
Utilize the difference miRNA screening of 3 groups of samples of F check carrying out of multiple comparisons check (RVM), according to Pvalue＜0.01, FDR＜0.01 screening obtains differential expression miRNA.
3.2miRNA expression trend analysis
Obtain the difference miRNA of 3 groups of samples by screening after, logical order (P-R-B) according to sample, based on the expression values of miRNA under each sample, difference miRNA is expressed the cluster of trend, according to cluster result distinctive miRNA under every kind of treated state is sorted out, screening obtains the expression trend of difference miRNA.
3.3 feature representation miRNA group's affirmation
The miRNA (see figure 1) that (among the B) in opposing and when removing Virus State is presented special low expression trend, obtain all target genes of difference miRNA regulation and control by search Sanger database, above-mentioned target gene is carried out function (Gene Ontology, GO) and the significance analysis of signal transduction pathway (pathway), seek and have remarkable function and participate in the target gene that the significance signal forwards path to; In the regulated and control network (GeneRelNet) of signal transduction network (Signal-Net) and gene, seek the target gene that is in key event and critical role simultaneously, find out the pairing miRNA of the target gene that obtains after the above-mentioned data integration, thereby finishing screen is selected the miRNA construction feature expression miRNA group's (table 1) with the meaning represented.
Specifically expressing miRNA group of the present invention, be expected to detect the expression level of these miRNA in the sample, according to the expression level diagnosis of aids of these miRNA and screen anti-AIDS cell drug based on the method that single, a plurality of or whole miRNA wherein set up chip, molecular hybridization and RT-PCR.
Claims (2)
1. one group of hiv virus target cell CD4+T cell susceptible and support the specifically expressing miRNA group of HIV-1, it is characterized in that the miRNA title that this specifically expressing miRNA group comprises is respectively hsa-let-7b, hsa-let-7c, hsa-let-7g, hsa-let-7i, hsa-mir-140-3p, hsa-mir-150, hsa-mir-181a, hsa-mir-22, hsa-mir-26a, hsa-mir-26b, hsa-mir-342-3p, hsa-mir-342-5p, it is the sign of the anti-AIDS of combination conduct eliminating cell drug partly or entirely; This group miRNA is low the expression when CD4+T cell resistance and removing HIV-1 state.
2. the specifically expressing miRNA group of the described hiv virus target cell of claim 1 CD4+T cell susceptible and support HIV-1 is characterized in that 5 miRNA are made up of the nucleotide sequence shown in the SEQ ID NO:1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010293265 CN101974531A (en) | 2010-09-27 | 2010-09-27 | Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010293265 CN101974531A (en) | 2010-09-27 | 2010-09-27 | Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101974531A true CN101974531A (en) | 2011-02-16 |
Family
ID=43574439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010293265 Pending CN101974531A (en) | 2010-09-27 | 2010-09-27 | Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101974531A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2546358A1 (en) * | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
| EP2756102A1 (en) * | 2011-09-13 | 2014-07-23 | Commonwealth Scientific and Industrial Research Organisation | Detection of viral infection |
| EP3178943A3 (en) * | 2013-12-17 | 2017-08-09 | Csir | A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds |
-
2010
- 2010-09-27 CN CN 201010293265 patent/CN101974531A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 《Nature Medicine》 20071031 Huang JL等 Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+T lymphocytes 1241-1247 1-2 第13卷, 第10期 2 * |
| 《Science》 19960628 Levine BL等 Antiviral effect and ex vivo CD4(+) T cell proliferation in HIV-positive patients as a result of CD28 costimulation 1939-1943 1-2 第272卷, 第5270期 2 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2546358A1 (en) * | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
| WO2013010906A3 (en) * | 2011-07-15 | 2013-03-14 | Laboratorios Del Dr. Esteve, S.A. | Methods and reagents for efficient control of hiv progression |
| EP2756102A1 (en) * | 2011-09-13 | 2014-07-23 | Commonwealth Scientific and Industrial Research Organisation | Detection of viral infection |
| EP2756102A4 (en) * | 2011-09-13 | 2015-04-15 | Commw Scient Ind Res Org | Detection of viral infection |
| EP3178943A3 (en) * | 2013-12-17 | 2017-08-09 | Csir | A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds |
| US10214779B2 (en) | 2013-12-17 | 2019-02-26 | Csir | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds |
| US10351916B2 (en) | 2013-12-17 | 2019-07-16 | Csir | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bruchova et al. | Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis | |
| US9868988B2 (en) | Method to assess human allograft status from microrna expression levels | |
| CN109666728A (en) | Using the method and composition of the Microrna assessment dysgenesia patient of immunocyte source property | |
| CN101368213A (en) | Blood serum minuteness ribonucleic acid reagent kit and application in early diagnosis of hepatitis B | |
| CN102666878A (en) | Markers, methods, biochips and kits for milk qualit y detection | |
| CN106867967A (en) | The LM3 cell lines and its construction method of Midkine stable low-expressions | |
| CN112176021A (en) | Method for accurately predicting drug use of cancer patient through in-vitro construction | |
| CN105177132A (en) | RT-PCR method for quantitatively detecting miRNA | |
| CN101684488B (en) | Small RNA and application thereof | |
| Cho et al. | MicroRNA expression profiling in neurogenesis of adipose tissue-derived stem cells | |
| CN101974531A (en) | Specific expression miRNA group susceptible to and supporting HIV-1 (Human Immunodeficiency Virus-Type 1) in CD4+T cell of HIV target cell | |
| CN101974530A (en) | Specific expression miRNA group of HIV (Human Immunodeficiency Virus) target cell CD4+T cell for resisting against and clearing HIV-1 | |
| CN106480033A (en) | A kind of ring-type circRNA 005365 gene related to leukemia and application thereof | |
| CN109022568A (en) | It is a kind of for the microRNA biomarker of diagnosis of rheumatoid arthritis and its application | |
| CN106244679B (en) | MiR-100 inhibitor is reducing the purposes in cancer metastasis | |
| CN110317878A (en) | A kind of long-chain non-coding RNA and its application for bladder cancer diagnosis and treatment monitoring | |
| CN108034719B (en) | Application of GINS4 gene or GINS4 protein as biomarker in preparation of lung adenocarcinoma pre-diagnosis reagent | |
| CN106434667B (en) | Relevant ring-type circRNA-016901 gene of a kind of leukaemia and application thereof | |
| Chi et al. | Interferon‑γ alters the microRNA profile of umbilical cord‑derived mesenchymal stem cells | |
| CN101368180A (en) | Small RNA numerator for differentiation of mesenchyma stem cell into hematopoiesis cell and function target point thereof | |
| CN107513571A (en) | MiRNA application | |
| Stroncek et al. | Quality assessment of cellular therapies: the emerging role of molecular assays | |
| CN114032237A (en) | Circular non-coding RNA circSTK39 and application thereof in preventing and treating atherosclerosis | |
| CN106191058B (en) | A kind of relevant ring-type circRNA-011235 genes of leukaemia and application thereof | |
| CN109652529A (en) | Osteoporosis specificity miRNA, composition and its diagnostic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110216 |